Sai Life Sciences Limited
|
Lot Size
1 Lot = 27 Qty |
Min Investment
₹14823 |
|
Subscription
Oversubscribed |
Listing Gain
201(Points) |
IPO Details
|
Open Date
Dec 11, 2024 |
Close Date
Dec 13, 2024 |
Allotment Date
Dec 16, 2024 |
|
Allotment Date
Dec 16, 2024 |
Refund Initiation
Dec 17, 2024 |
Demat Transfer
Dec 17, 2024 |
|
Listing Date
Dec 18, 2024 |
Fresh Issue
950 |
Offer For Sale
2092.62 |
|
Issue Price
₹522 to ₹549 |
Face Value
₹1 |
Issue Type
Fresh Issue |
|
Total Issue Size
3042.62 CR |
QIB + NII Quota
50 + 15% |
Retail Quota
35% |
|
Listing On
NSE & BSE |
Registrar
KFin Technologies Private Ltd |
Company Financial Rusult In Crore
| PERIOD | ASSET | REVENUE | PROFIT |
|---|---|---|---|
| 30-Sep-2024 | 2476.78 | 693.35 | 28.01 |
| 31-Mar-2024 | 2275.14 | 1494.27 | 82.81 |
| 31-Mar-2023 | 2186.65 | 1245.11 | 9.99 |
| 31-Mar-2022 | 2164.23 | 897.74 | 6.23 |
About Sai Life Sciences Limited
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023. The services were offered across the US, the UK, Europe, and Japan.
The companys business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
Sai Life Sciences - Strength and Weakness
Strength
- Sai Life Sciences is one of India largest CRDMOs by revenue.
- Diverse product portfolio with 38 products and 7 blockbuster drugs.
- Strong R&D infrastructure, offering integrated services and global talent.
- Fastest-growing CRDMO with improving profitability and revenue growth metrics.
Weakness
- Dependent on biotechnology and pharmaceutical customers, facing industry-specific risks.
- Manufacturing delays or interruptions could lead to higher costs and risks.
- Heavy reliance on international revenue, facing risks of operational delays.